Roxithromycin and erythromycin in chlamydia-negative non-gonococcal urethritis.
The clinical efficacy and safety of roxithromycin 300 mg once a day was compared with that of erythromycin 500 mg twice a day in 87 men with chlamydia-negative non-gonococcal urethritis. In the roxithromycin group the clinical efficacy rate was 88% on day 8 and between 78% and 84% on day 21. In the erythromycin group the clinical efficacy rate was 98% on day 8 and 86% on day 21, a non-significant difference. Side effects were mainly gastrointestinal, occurring in about 15% of patients receiving each treatment.
Worm
A M
AM
Department of Dermato-Venereology, Bispebjerg Hospital, Copenhagen, Denmark.
D002690:Chlamydia Infections / Q000188:drug therapy*; D004311:Double-Blind Method; D004917:Erythromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011897:Random Allocation; D015575:Roxithromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014526:Urethritis / Q000188:drug therapy*
D015575:Roxithromycin; D004917:Erythromycin